In a letter published in the British Medical Journal, I discuss why the UK government must be more proactive about drug addressing shortages in the NHS.
The lack of drugs such as methylphenidate required for the treatment of attention deficit/hyperactivity disorder (ADHD) is the latest of many medication shortages we have seen in the UK in recent years.1 These shortages are now too frequent and waste the time of NHS staff such as general practitioners and pharmacists who have to spend time counselling patients and sourcing alternative drugs instead of focusing on more relevant work. They are also very stressful for patients who risk going without key drugs with potentially adverse consequences for their health. For people with ADHD, for example, this could mean going without medication that they require to function effectively at work and school and in their personal relationships.
We need a much more proactive approach from the government, which needs to work with drugs manufacturers and wholesalers to ensure that the NHS has adequate supplies of key drugs to prevent such problems occurring in the future. This could include better data on drug supply and demand to identify problems before they occur; improving local manufacturing capacity in the UK for essential drugs needed by the NHS; price incentives for suppliers; and international collaboration to ensure continuity of drug supply. Moreover, immediate support mechanisms should be put in place for primary care teams grappling with the increased workload caused by these shortages. Patients too could benefit from help such as national helplines or online support to allow them to cope better with the consequences of drug shortages.
Until we see active intervention by government, working in partnership with the NHS and industry, patients in the UK will continue to be affected and the time of NHS staff will continue to be wasted because of drug shortages.